GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is a great stock for any portfolio. Indeed, the company has all the best qualities you could ask for — a high dividend yield, attractive valuation healthy balance sheet, dominant market position and a reliable cash flow.
At present, Glaxo’s shares support a dividend yield of 5.1%. The company trades at a forward P/E of 16.9, which may seem high, but Glaxo trades at a significant discount to its international peer group.
Lacking growth
Still, one thing Glaxo lacks is growth. The company’s earnings per share are set to fall 5% next year and City analysts expect the company to report moderate EPS growth of 5% during 2016 — nothing to get excited about.
That’s where SkyePharma (LSE: SKP) comes into the picture. Skye has worked with Glaxo in the past. Some of the company’s key technologies are designed to help the delivery of oral and inhalation pharmaceutical products.
Glaxo is a specialist in oral treatments. The global pharma group currently produces two treatments that use technology licensed by Skye. Skye’s royalty payments from these treatments are capped at £9m per annum.
Rapid growth
While Glaxo’s glacial growth rate may put some investors off, Skye’s most attractive quality is the company’s projected growth rate. City analysts expect the company’s earnings per share to expand at a high single-digit rate over the next three years, as sales of the company’s key products continue to expand.
In particular, Skye has launched eight new products in the past three years and several more are still in the pipeline. These include SKP-2075, for chronic obstructive pulmonary disease and Soctec™, a concept for a novel, proprietary gastro-retentive drug delivery platform.
Skye is also pumping cash into research and development. R&D spending totalled £0.5m during 2013 but then jumped to £4.5m for fiscal 2014 and is expected to hit £10m during 2015. With a strong pipeline of treatments under development and more cash being devoted to R&D spending, Skye is charting a course for rapid growth over the next decade or so.
Unfortunately, with such bright growth prospects, Skye isn’t cheap. The company currently trades at a forward — 2015 — P/E of 15.2, falling to 14.4 during 2016.
Nevertheless, Skye deserves a premium valuaion and I wouldn’t rule out a bid from a large peer, like Glaxo, in the near future.
Foolish summary
So, if you’re looking for a dynamic growth and income pharma duo for your portfolio, Glaxo and Skye look to be the perfect combination. While Glaxo offers income, Skye is growing rapidly and the company’s increasing R&D budget will only serve to drive further growth in the future.
